<DOC>
	<DOCNO>NCT00095316</DOCNO>
	<brief_summary>Adults admit intensive care unit risk variety complication . One frequent complication development new infection . Infections due fungus call Candida particular concern . This study test possibility caspofungin , new therapy fungal infection , may reduce rate Candida infection subject risk .</brief_summary>
	<brief_title>Caspofungin Study Fungal Infections Adults Critical Care Settings</brief_title>
	<detailed_description>A Randomized , Double-Masked Trial Caspofungin ( 50 mg/day ) Versus Placebo Prophylaxis Invasive Candidiasis HighRisk Adults Critical Care Setting 28 day observation primary outcome 7 day study therapy . The primary objective study evaluate efficacy caspofungin prophylaxis invasive candidiasis high-risk ICU patient oppose receive placebo whereas secondary objective follow : To evaluate utility surrogate marker diagnosis invasive candidiasis , assess effect colonization risk factor develop disease , evaluate safety prophylactic caspofungin subject discontinue study due drug-related adverse event versus subject 1 drug-related adverse event evaluate all-cause mortality .</detailed_description>
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<criteria>Nonpregnant subject &gt; /= 18 year age ; admission ICU precede 3 day ( minimum 2 day ICU ) expect stay ICU minimum 2 additional day ; subject must least 1 follow : receive least one dose systemic antibiotic one ICU day study entry continue receive antibiotic time enrollment , and/or presence central venous catheter time enrollment one additional day current ICU stay , least 2 follow : use total parenteral nutrition Days 14 ICU stay ; type dialysis Days 14 ICU stay ; inpatient surgery do general anesthesia epidural block 7 day prior ICU admission* ; pancreatitis ( document compute tomography ( CT ) scan lipase &gt; 1,000 u/L ) 7 day prior ICU admission ; 1 dose systemic steroid ( prednisone equivalent dose &gt; /=20 mg per dose ) 7 day prior ICU admission ; and/or use 1 dose systemic immunosuppressive agent ( azathioprine , tacrolimus , sirolimus , mycophenolate , monoclonal antibody , tumor necrosis factor [ TNF ] immunomodulators ) 7 day prior ICU admission . Excludes placement vascular catheter . Subjects allergy intolerance caspofungin echinocandin analog ; absolute neutrophil count &lt; 500/mm3 entry likely develop count therapy ; diagnosis HIV , aplastic anemia , chronic granulomatous disease ; moderate severe hepatic insufficiency define Child Pugh score 7 great cirrhosis due cause ; pregnancy breastfeeding ; subject unlikely survive 2 day ; subject receive systemic antifungal therapy within 7 day prior study entry ; subject document active , proven , probable invasive fungal infection within 7 day prior study entry ; subject previously enrol trial ; subject currently receive another investigational agent receive investigational agent within 7 day prior study entry ; subject ICU 5 day prior enrollment study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>candidiasis , caspofungin , fungal infection , prophylaxis</keyword>
</DOC>